ArticleAdvances in therapy2024

De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate.

Mark Gudesblatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.